Last reviewed · How we verify
NCT04675710
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Phase 2 trial testing Conventional Surgery in Thyroid Gland Anaplastic Carcinoma in 30 participants. Participants enrolled and being followed up; not accepting new ones.
30 October 2026
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 24 June 2021 |
| Primary completion | 30 October 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Conventional Surgery
- Dabrafenib (dabrafenib) — full drug profile →
- Intensity-Modulated Radiation Therapy
- Pembrolizumab (pembrolizumab) — full drug profile →
- Quality-of-Life Assessment
- Trametinib (trametinib) — full drug profile →
Conditions studied
- Thyroid Gland Anaplastic Carcinoma — all drugs for Thyroid Gland Anaplastic Carcinoma →
- Thyroid Gland Squamous Cell Carcinoma — all drugs for Thyroid Gland Squamous Cell Carcinoma →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Thyroid Gland Anaplastic Carcinoma or Thyroid Gland Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in cell growth. It may increase the growth and spread of tumor cells. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab, dabrafenib, and trametinib may help to control BRAF V600E-mutated anaplastic thyroid cancer when given before surgery.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME, Kim HJ, Kim DR. · · 2023 · cited 519× · PMID 38105263 · DOI 10.1038/s41392-023-01705-z -
Anaplastic Thyroid Carcinoma: An Update.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, et al · · 2022 · cited 110× · PMID 35205809 · DOI 10.3390/cancers14041061 -
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF<sup>V600E</sup> Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.
Zhao X, Wang JR, Dadu R, Busaidy NL, et al · · 2023 · cited 79× · PMID 36762947 · DOI 10.1089/thy.2022.0504 -
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.
Wang JR, Montierth M, Xu L, Goswami M, et al · · 2022 · cited 53× · PMID 35977347 · DOI 10.1200/po.21.00504 -
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, et al · · 2024 · cited 42× · PMID 39446377 · DOI 10.1001/jamaoncol.2024.4729 -
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829 -
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
Avery TY, Köhler N, Zeiser R, Brummer T, et al · · 2022 · cited 31× · PMID 35965494 · DOI 10.3389/fonc.2022.931774 -
What is the status of immunotherapy in thyroid neoplasms?
Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J. · · 2022 · cited 30× · PMID 35992118 · DOI 10.3389/fendo.2022.929091
Verify or expand the search:
- PubMed search for NCT04675710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Conventional Surgery
Trials testing the same drug.
- NCT04729959 — Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Gliob · Phase 2 · active not recruiting
- NCT04221438 — Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement · Phase 2 · terminated
- NCT05252260 — Comparison of Diode Laser-Assisted Vestibuloplasty And Conventional Vestibuloplasty · NA · completed
- NCT03808779 — A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma. · NA · unknown
- NCT03784326 — Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastro · Phase 2 · active not recruiting
Other recruiting trials for Thyroid Gland Anaplastic Carcinoma
Currently open trials in the same condition.
- NCT06639191 — [177Lu]Lu-AKIR001 First-in-human Study · EARLY_PHASE1 · recruiting
- NCT04759911 — Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer · Phase 2 · active not recruiting
- NCT03975231 — Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer · Phase 1 · recruiting
- NCT03449108 — LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC · Phase 2 · active not recruiting
- NCT03181100 — Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer · Phase 2 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04675710 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04675710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing